alpha-naphthoflavone has been researched along with Cancer of Prostate in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Beloglazkina, EK; Ber, AP; Borisova, YA; Chepikova, OE; Erofeev, A; Gorelkin, P; Khazanova, ES; Khudyakov, AD; Kolmogorov, VS; Kovalev, S; Machulkin, AE; Majouga, AG; Nimenko, EA; Pankratov, AA; Petrov, SA; Plotnikova, EA; Pokrovsky, VS; Polshakov, VI; Shafikov, RR; Skvortsov, DA; Smirnova, GB; Uspenskaya, AA; Vaneev, AN; Zamyatnin, AA; Zyk, NU; Zyk, NV | 1 |
Cao, C; Chen, P; Chen, W; Wang, M; Wang, S; Ye, W; Zhang, K; Zhang, X; Zhou, C; Zhou, W | 1 |
Burnstein, KL; Hayakawa, K; Kizu, R; Klinge, CM; Mizokami, A; Okamura, K; Toriba, A | 1 |
3 other study(ies) available for alpha-naphthoflavone and Cancer of Prostate
Article | Year |
---|---|
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
Topics: Antigens, Surface; Cell Line, Tumor; Coordination Complexes; Glutamate Carboxypeptidase II; Humans; Male; Microsomes, Liver; Oligopeptides; Prostatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Topics: Antineoplastic Agents; Benzoflavones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytochrome P-450 CYP1B1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Solubility; Structure-Activity Relationship | 2021 |
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
Topics: Adenocarcinoma; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Benzoflavones; beta-Galactosidase; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Luciferases; Male; Nitriles; Polycyclic Aromatic Hydrocarbons; Proadifen; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Aryl Hydrocarbon; Saccharomyces cerevisiae; Tosyl Compounds; Vehicle Emissions | 2003 |